CLR_15_03 (R/R)

A safety, tolerability, pharmacokinetic study of K0706 in healthy and chronic myeloid leukemia (CML) subjects

Study treatments

Oral administration of K0706

Inclusion criteria

• Subjects diagnosed with Ph+ CML-chronic phase, Ph+ CML accelerated phase, Ph+ CML blast crisis or Ph+ Acute Lymphoblastic Leukemia
• ECOG score of 0, 1 or 2

Exclusion criteria

• Any major surgery, as determined by the investigator, within 4 weeks of study drug administration
• Inability to undergo venipuncture and/or tolerate venous access

Participating sites

• University Hospital Leuven Gasthuisberg
• ZNA